PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2019166830) EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINE
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/166830 International Application No.: PCT/GB2019/050588
Publication Date: 06.09.2019 International Filing Date: 01.03.2019
IPC:
A61K 39/08 (2006.01) ,C07K 14/33 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
08
Clostridium, e.g. Clostridium tetani
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195
from bacteria
33
from Clostridium (G)
Applicants:
ONE HEALTH VENTURES LTD [GB/GB]; 6th Floor, St Magnus House 3 Lower Thames Street London EC3R 6HD, GB
Inventors:
TITBALL, Richard William; GB
BOKORI-BROWN, Monika; GB
MORCRETTE, Helen; GB
LEWIS, Nicholas Peter; GB
Agent:
SPINNER, David; GB
Priority Data:
1803401.702.03.2018GB
1900361.510.01.2019GB
Title (EN) EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINE
(FR) TOXINE EPSILON PROVENANT DE CLOSTRIDIUM PERFRINGENS EN TANT QUE VACCIN
Abstract:
(EN) This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: : enterotoxemia (ET), multiple sclerosis(MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS),neuromyelitis optica spectrum disorder(NMOSD),optic neuritis(ON), neuromyelitis optica (NMO), myelitis,myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4(AQP-4) and/or astrocyte damage,and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need. The methods comprise administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interfereswith epsilontoxin (ETX) produced by Clostridium perfringens type B or type D bacterial strain, an ETX-binding receptor, or an interaction of ETX with its binding receptor so as to inhibit or suppress ETX modulated receptor signalling activities. The invention also provides novel polypeptides useful as a vaccine against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.
(FR) La présente invention concerne des procédés et des compositions pour détecter, diagnostiquer, prévenir, traiter ou améliorer les symptômes d'une affection démyélinisante choisie parmi : l'entérotoxémie (ET), la sclérose en plaques (SEP), la SEP cliniquement définie (SEPCD), le syndrome cliniquement isolé (SCI), le trouble du spectre de la neuromyélite optique (TSNMO), la névrite optique (NO), la neuromyélite optique (NMO), la myélite, la myélite transverse (MT), une maladie ou un état caractérisé par l'augmentation ou la présence d'anticorps contre l'aquaporine-4(AQP-4) et/ou les lésions d’astrocytes, et l'encéphalomyélite disséminée aiguë (EMDA) chez un sujet humain ou animal en ayant besoin. Les procédés comprennent l'administration au sujet d'une composition comprenant une quantité efficace d'un agent qui interfère directement ou indirectement avec la toxine epsilon (ETX) produite par la souche bactérienne de type B ou de type D de Clostridium perfringens, un récepteur de liaison de ETX, ou une interaction de ETX avec son récepteur de liaison de façon à inhiber ou à supprimer des activités de signalisation de récepteur modulé de ETX. L'invention concerne également de nouveaux polypeptides utiles en tant que vaccin contre des maladies provoquées par ou associées à la toxine Epsilon de Clostridium perfringens.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)